Companies Revance Therapeutics
Revance Therapeutics (RVNC): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Revance Therapeutics no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers53rd pct.Of 20 peer CEOs
CEO pay ratio42:1To the median employee
CEO pay, last three years
- $7,105,916FY2021
- $6,606,916FY2022
- $10,068,915FY2023
CEO total pay was $10,068,915 in fiscal 2023, up from $6,606,916 in fiscal 2022.
FY2023: salary $720,000 · bonus $0 · stock awards $8,810,731 · option awards $0
Executives and directors
Dustin Sjuts · PresidentDwight Moxie · General CounselMark Foley · CEOTobin Schilke · CFOAngus C. Russell · Chair of the BoardCarey O'Connor Kolaja · Independent DirectorChristian W. Nolet · Independent DirectorJill Beraud · Independent DirectorJulian S. Gangolli · Independent DirectorOlivia C. Ware · Independent DirectorPhilip J. Vickers, Ph.D · Former director (through FY2023)Vlad Coric, M.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Revance Therapeutics in fiscal 2023?
As disclosed, Mark Foley (Chief Executive Officer) was the highest-paid executive at Revance Therapeutics in fiscal 2023, with total compensation of $10,068,915.
How does Revance Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Mark Foley's total compensation ranked at the 53rd percentile of Revance Therapeutics's disclosed peer group.
What is Revance Therapeutics's CEO-to-median employee pay ratio?
As disclosed, Revance Therapeutics's CEO-to-median employee pay ratio was 42:1.
How did shareholders vote on Revance Therapeutics's executive compensation?
As disclosed, 73.66% of shareholders supported Revance Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Revance Therapeutics spend in total on board compensation for fiscal 2023?
As disclosed, Revance Therapeutics reported total board compensation of $1,434,473 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Foley | $720,000 | $0 | $8,810,731 | $0 | $522,720 | $0 | $15,464 | $10,068,915 |
| Chief Executive Officer | ||||||||
| Dustin Sjuts | 535,000 | 0 | 2,753,384 | 917,555 | 336,622 | 0 | 39,069 | 4,581,630 |
| President | ||||||||
| Tobin Schilke | 480,649 | 0 | 2,172,702 | 1,069,863 | 237,440 | 0 | 13,491 | 3,974,145 |
| Chief Financial Officer | ||||||||
| Dwight Moxie | 473,295 | 0 | 1,885,760 | 928,565 | 229,075 | 0 | 11,450 | 3,528,145 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Mark Foley | $10,068,915 | $6,606,916 | $7,105,916 | ↑ +3,461,999 |
| Dustin Sjuts | 4,581,630 | 2,592,449 | 3,230,411 | ↑ +1,989,181 |
| Tobin Schilke | 3,974,145 | 2,279,831 | 2,534,794 | ↑ +1,694,314 |
| Dwight Moxie | 3,528,145 | 2,269,921 | 2,244,615 | ↑ +1,258,224 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The overall objectives of our executive compensation policies and programs are to: attract, retain and motivate superior executive talent; provide incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value, as well as to facilitate executive retention; align our executives' interests with those of our stockholders; link pay to Company performance; and offer pay opportunities that are competitive with the biotechnology market in which we compete in order to recruit and retain top talent, while maintaining reasonable cost and dilution to our stockholders.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Mark Foley | PSU | 2023-01-31 | 63,515 | 254,058 | — | 508,116 | $8,810,731 |
| Dwight Moxie | EQUITY | — | — | — | — | — | — |
| Dwight Moxie | PSU | 2023-01-31 | 13,594 | 54,376 | — | 108,752 | 1,885,760 |
| Dustin Sjuts | PSU | 2023-01-31 | 19,849 | 79,394 | — | 158,788 | 2,753,384 |
| Tobin Schilke | OPTION | 2023-01-31 | — | — | 50,435 | — | 1,069,863 |
| Dustin Sjuts | OPTION | 2023-01-31 | — | — | 43,255 | — | 917,555 |
| Tobin Schilke | EQUITY | — | — | — | — | — | — |
| Tobin Schilke | PSU | 2023-01-31 | 15,663 | 62,650 | — | 125,300 | 2,172,702 |
| Dustin Sjuts | EQUITY | — | — | — | — | — | — |
| Dwight Moxie | OPTION | 2023-01-31 | — | — | 43,774 | — | 928,565 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Mark Foley | $0 | $8,810,731 | $0 | 100.0% |
| Dwight Moxie | 0 | 1,885,760 | 928,565 | 67.0% |
| Dustin Sjuts | 0 | 2,753,384 | 917,555 | 75.0% |
| Tobin Schilke | 0 | 2,172,702 | 1,069,863 | 67.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Tobin Schilke | Option | 2,032 | 22.32 | — |
| Dustin Sjuts | Option | 2,084 | 22.32 | — |
| Dwight Moxie | RSU | 6,449 | — | 56,687 |
| Dwight Moxie | Option | 7,084 | 25.93 | — |
| Tobin Schilke | RSU | 7,540 | — | 66,277 |
| Dustin Sjuts | RSU | 7,540 | — | 66,277 |
| Dwight Moxie | Option | 10,209 | 28.01 | — |
| Tobin Schilke | Option | 11,937 | 28.01 | — |
| Dustin Sjuts | Option | 11,937 | 28.01 | — |
| Dustin Sjuts | RSU | 11,974 | — | 105,251 |
| Mark Foley | RSU | 13,572 | — | 119,298 |
| Dwight Moxie | PSU | 14,000 | — | 123,060 |
| Tobin Schilke | PSU | 18,000 | — | 158,220 |
| Dustin Sjuts | PSU | 20,000 | — | 175,800 |
| Mark Foley | Option | 21,486 | 28.01 | — |
| Dustin Sjuts | Option | 30,884 | 13.08 | — |
| Dustin Sjuts | Option | 33,343 | 34.68 | — |
| Dwight Moxie | Option | 33,743 | 34.68 | — |
| Tobin Schilke | Option | 36,884 | 13.08 | — |
| Dwight Moxie | Option | 36,884 | 13.08 | — |
| Tobin Schilke | Option | 38,877 | 34.68 | — |
| Dwight Moxie | PSU | 54,376 | — | 477,965 |
| Tobin Schilke | PSU | 62,650 | — | 550,694 |
| Mark Foley | Option | 77,624 | 13.08 | — |
| Dustin Sjuts | PSU | 79,394 | — | 697,873 |
| Mark Foley | PSU | 254,058 | — | 2,233,170 |
| Mark Foley | PSU | 344,000 | — | 3,023,760 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Vlad Coric, M.DIndependent · Compensation | $46,820 | $187,335 | $187,335 | — | $0 | $421,490 |
| Angus C. RussellIndependent · Board Chair · Compensation · Nominating and Corporate Governance (Chair) | 108,500 | 118,778 | 118,755 | — | 0 | 346,033 |
| Jill BeraudIndependent · Compensation (Chair) · Brand Strategy | 80,000 | 118,778 | 118,755 | — | 0 | 317,533 |
| Christian W. NoletIndependent · Audit (Chair) · Nominating and Corporate Governance | 77,500 | 118,778 | 118,755 | — | 0 | 315,033 |
| Julian S. GangolliIndependent · Audit · Brand Strategy | 67,500 | 118,778 | 118,755 | — | 0 | 305,033 |
| Carey O'Connor KolajaIndependent · Audit · Nominating and Corporate Governance | 66,650 | 118,778 | 118,755 | — | 0 | 304,183 |
| Olivia C. WareIndependent · Nominating and Corporate Governance | 57,500 | 118,778 | 118,755 | — | 0 | 295,033 |
| Philip J. Vickers, Ph.DIndependent · Departed during FY | 30,000 | — | — | — | 0 | 30,000 |
| Mark J. FoleyEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $225,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 15,000 |
| Stock ownership guideline | 3x annual cash retainers for independent directors (excluding committee retainers) |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $534,470 |
| Equity awards (grant-date value) | $900,003 |
| All other compensation | $0 |
| Total cost of the board | $1,434,473 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Revance Therapeutics as a peer
Companies that benchmark against RVNC
9 companies name RVNC as a compensation peer
The list of companies that name RVNC as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ChemoCentryxSGMO Sangamo Therapeutics Global Blood TherapeuticsINSM InsmedITCI Intra-Cellular TherapiesKPTI Karyopharm TherapeuticsNVRO NevroTBPH Theravance BiopharmaAGIO Agios PharmaceuticalsBPMC Blueprint MedicinesCSII Cardiovascular SystemsDVAX Dynavax TechnologiesCHRS Coherus BioSciencesSUPN Supernus PharmaceuticalsHRTX Heron TherapeuticsFOLD Amicus Therapeutics ArtiCureCORT Corcept TherapeuticsDCPH Deciphera PharmaceuticalsGKOS Glaukos
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Supernus Pharmaceuticals | 2025 | Jack Khattar | $1,036,000 | $6,535,029 | $7,031,545 | $846,930 | $15,501,557 |
| 2 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 3 | Insmed | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 4 | Blueprint Medicines | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 5 | Glaukos | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 6 | Nevro | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 7 | Intra-Cellular Therapies | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 8 | Revance Therapeutics | 2023 | Mark Foley | 720,000 | 8,810,731 | 0 | 522,720 | 10,068,915 |
| 9 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 10 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 11 | Deciphera Pharmaceuticals | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 12 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 13 | Heron Therapeutics | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 14 | Coherus BioSciences | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 15 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 16 | Theravance Biopharma | 2025 | Rick Winningham | 1,047,431 | 0 | 0 | 419,182 | 1,472,019 |
| — | Sangamo Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Cardiovascular Systems | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Revance Therapeutics | 96.8% | PSU 100 | No | FW Cook |
| Agios Pharmaceuticals | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Amicus Therapeutics | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Blueprint Medicines | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| Cardiovascular Systems | not disclosed | not disclosed | not disclosed | not disclosed |
| Coherus BioSciences | not disclosed | Option 100 | not disclosed | Aon |
| Corcept Therapeutics | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Deciphera Pharmaceuticals | 110% | Option 50 · PSU 50 · RSU 25 | No | Pearl Meyer & Partners, LLC |
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Glaukos | not disclosed | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Heron Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Insmed | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Intra-Cellular Therapies | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| Nevro | 53.7% | not disclosed | No | Aon |
| Sangamo Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Supernus Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Theravance Biopharma | not disclosed | RSU 100 | not disclosed | Frederic W. Cook & Co. (FW Cook) |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-05-01 | 51,554,931 | 18,083,102 | 353,860 | 73.66% | Passed |
| 2023 | 2023-05-03 | 60,543,078 | 2,144,177 | 80,254 | 96.46% | Passed |
| 2022 | 2022-05-04 | 36,151,026 | 10,270,358 | 77,615 | 77.75% | Passed |
| 2021 | 2021-05-05 | 39,936,027 | 7,513,255 | 124,700 | 83.95% | Passed |
| 2020 | 2020-05-14 | 21,647,238 | 18,922,649 | 831,233 | 52.29% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-05-01 | 73.66%a |
| 2023 | 2023-05-03 | 96.46%b |
| 2022 | 2022-05-04 | 77.75%c |
a. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 42 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $238,081 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Mark J. Foley | Director | 2024-12-31 | A | 1,000 | $2 | $2,185 | Common | Form 4 ↗ |
| Tobin Schilke | CFO | 2024-12-31 | A | 1,000 | 2 | 2,185 | Common | Form 4 ↗ |
| Tobin Schilke | CFO | 2025-02-03 | A | 6,888 | 0 | 0 | Common | Form 4 ↗ |
| Mark J. Foley | Director | 2025-02-03 | A | 27,933 | 0 | 0 | Common | Form 4 ↗ |
| Dwight Moxie | CLO & GC | 2025-02-03 | A | 5,979 | 0 | 0 | Common | Form 4 ↗ |
| Dwight Moxie | CLO & GC | 2025-02-04 | D | 47,815 | 4 | 174,525 | Common | Form 4 ↗ |
| Julian S. Gangolli | Director | 2025-02-04 | D | 30,106 | 4 | 109,887 | Common | Form 4 ↗ |
| Angus C. Russell | Director | 2025-02-04 | D | 36,506 | 4 | 133,247 | Common | Form 4 ↗ |
| Christian W. Nolet | Director | 2025-02-04 | D | 28,606 | 4 | 104,412 | Common | Form 4 ↗ |
| Jill Beraud | Director | 2025-02-04 | D | 28,606 | 4 | 104,412 | Common | Form 4 ↗ |
| Vlad Coric | Director | 2025-02-04 | D | 5,784 | 4 | 21,112 | Common | Form 4 ↗ |
| Erica Jordan | Chief Commercial Officer | 2025-02-04 | D | 6,922 | 4 | 25,265 | Common | Form 4 ↗ |
| David Hollander | CMO & Global Therapeutics Lead | 2025-02-04 | D | 9,733 | 4 | 35,525 | Common | Form 4 ↗ |
| Tobin Schilke | CFO | 2025-02-04 | D | 97,999 | 4 | 357,696 | Common | Form 4 ↗ |
| Mark J. Foley | Director | 2025-02-04 | D | 110,913 | 4 | 404,832 | Common | Form 4 ↗ |
| Mark J. Foley | Director | 2025-02-04 | D | 996,935 | 4 | 3,638,813 | Common | Form 4 ↗ |
| Olivia C. Ware | Director | 2025-02-04 | D | 16,675 | 4 | 60,864 | Common | Form 4 ↗ |
| Carey O'Connor Kolaja | Director | 2025-02-04 | D | 16,561 | 4 | 60,448 | Common | Form 4 ↗ |
| Jill Beraud | Director | 2025-02-06 | D | 15,000 | — | — | Common | Form 4 ↗ |
| Vlad Coric | Director | 2025-02-06 | D | 15,000 | — | — | Common | Form 4 ↗ |
| Carey O'Connor Kolaja | Director | 2025-02-06 | D | 15,000 | — | — | Common | Form 4 ↗ |
| Erica Jordan | Chief Commercial Officer | 2025-02-06 | D | 107,942 | — | — | Common | Form 4 ↗ |
| David Hollander | CMO & Global Therapeutics Lead | 2025-02-06 | D | 95,212 | — | — | Common | Form 4 ↗ |
| Dwight Moxie | CLO & GC | 2025-02-06 | D | 95,979 | — | — | Common | Form 4 ↗ |
| Tobin Schilke | CFO | 2025-02-06 | D | 20,883 | — | — | Common | Form 4 ↗ |
| Tobin Schilke | CFO | 2025-02-06 | A | 20,883 | 0 | 0 | Common | Form 4 ↗ |
| Tobin Schilke | CFO | 2025-02-06 | D | 103,555 | — | — | Common | Form 4 ↗ |
| Mark J. Foley | Director | 2025-02-06 | D | 27,933 | — | — | Common | Form 4 ↗ |
| Christian W. Nolet | Director | 2025-02-06 | D | 15,000 | — | — | Common | Form 4 ↗ |
| Mark J. Foley | Director | 2025-02-06 | D | 84,686 | — | — | Common | Form 4 ↗ |
| Dwight Moxie | CLO & GC | 2025-02-06 | A | 18,125 | 0 | 0 | Common | Form 4 ↗ |
| Angus C. Russell | Director | 2025-02-06 | D | 15,000 | — | — | Common | Form 4 ↗ |
| Julian S. Gangolli | Director | 2025-02-06 | D | 15,000 | — | — | Common | Form 4 ↗ |
| Mark J. Foley | Director | 2025-02-06 | A | 84,686 | 0 | 0 | Common | Form 4 ↗ |
| Olivia C. Ware | Director | 2025-02-06 | D | 15,000 | — | — | Common | Form 4 ↗ |
| Dwight Moxie | CLO & GC | 2025-02-06 | D | 18,125 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (82 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Mark Foley. DEF 14A, filed 2024-03-21. Section “SUMMARY COMPENSATION TABLE FOR FISCAL YEARS 2023, 2022 AND 2021” · page 53. As printed: 10,068,915. View filing ↗
- Section 01, Dustin Sjuts. DEF 14A, filed 2024-03-21. Section “SUMMARY COMPENSATION TABLE FOR FISCAL YEARS 2023, 2022 AND 2021” · page 53. As printed: 4,581,630. View filing ↗
- Section 01, Tobin Schilke. DEF 14A, filed 2024-03-21. Section “SUMMARY COMPENSATION TABLE FOR FISCAL YEARS 2023, 2022 AND 2021” · page 53. As printed: 3,974,145. View filing ↗
- Section 01, Dwight Moxie. DEF 14A, filed 2024-03-21. Section “SUMMARY COMPENSATION TABLE FOR FISCAL YEARS 2023, 2022 AND 2021” · page 53. As printed: 3,528,145. View filing ↗
- Section 03, Mark Foley PSU. DEF 14A, filed 2024-03-21. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL YEAR 2023” · grants of plan-based awards table. View filing ↗
- Section 03, Dwight Moxie EQUITY. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Dwight Moxie PSU. DEF 14A, filed 2024-03-21. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL YEAR 2023” · grants of plan-based awards table. View filing ↗
- Section 03, Dustin Sjuts PSU. DEF 14A, filed 2024-03-21. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL YEAR 2023” · grants of plan-based awards table. View filing ↗
- Section 03, Tobin Schilke OPTION. DEF 14A, filed 2024-03-21. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL YEAR 2023” · grants of plan-based awards table. View filing ↗
- Section 03, Dustin Sjuts OPTION. DEF 14A, filed 2024-03-21. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL YEAR 2023” · grants of plan-based awards table. View filing ↗
- Section 03, Tobin Schilke EQUITY. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Tobin Schilke PSU. DEF 14A, filed 2024-03-21. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL YEAR 2023” · grants of plan-based awards table. View filing ↗
- Section 03, Dustin Sjuts EQUITY. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Dwight Moxie OPTION. DEF 14A, filed 2024-03-21. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL YEAR 2023” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A. Section “CEO Pay Ratio”. As printed: 42 : 1.
- Section 08, Vlad Coric, M.D. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 421,490. View filing ↗
- Section 08, Angus C. Russell. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 346,033. View filing ↗
- Section 08, Jill Beraud. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 317,533. View filing ↗
- Section 08, Christian W. Nolet. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 315,033. View filing ↗
- Section 08, Julian S. Gangolli. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 305,033. View filing ↗
- Section 08, Carey O'Connor Kolaja. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 304,183. View filing ↗
- Section 08, Olivia C. Ware. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 295,033. View filing ↗
- Section 08, Philip J. Vickers, Ph.D. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 30,000. View filing ↗
- Section 08, Mark J. Foley. DEF 14A, filed 2024-03-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Mark J. Foley 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tobin Schilke 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tobin Schilke 2025-02-03. Form 4, filed 2025-02-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Foley 2025-02-03. Form 4, filed 2025-02-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dwight Moxie 2025-02-03. Form 4, filed 2025-02-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dwight Moxie 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julian S. Gangolli 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angus C. Russell 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christian W. Nolet 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill Beraud 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vlad Coric 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erica Jordan 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Hollander 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tobin Schilke 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Foley 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Foley 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Olivia C. Ware 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carey O'Connor Kolaja 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill Beraud 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vlad Coric 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carey O'Connor Kolaja 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erica Jordan 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Hollander 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dwight Moxie 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tobin Schilke 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tobin Schilke 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tobin Schilke 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Foley 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christian W. Nolet 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Foley 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dwight Moxie 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angus C. Russell 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julian S. Gangolli 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Foley 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Olivia C. Ware 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dwight Moxie 2025-02-06. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-03. Item 5.07 · say-on-pay result. As reported: 73.66% (votes for as printed: 51,554,931). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-08. Item 5.07 · say-on-pay result. As reported: 96.46% (votes for as printed: 60,543,078). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-05-06. Item 5.07 · say-on-pay result. As reported: 77.75% (votes for as printed: 36,151,026). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 534,470 + equity 900,003 + all other 0 = 1,434,473, summed across the director compensation table rows.
- Supernus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. View filing ↗
- Corcept Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. View filing ↗
- Insmed, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed's own proxy. As printed: 14,467,393. View filing ↗
- Blueprint Medicines, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. View filing ↗
- Glaukos, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. View filing ↗
- Nevro, Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. View filing ↗
- Intra-Cellular Therapies, Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. View filing ↗
- Revance Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2024-03-21. CEO total compensation as printed in Revance Therapeutics's own proxy. As printed: 10,068,915. View filing ↗
- Amicus Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. View filing ↗
- Dynavax Technologies, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. View filing ↗
- Deciphera Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Deciphera Pharmaceuticals's own proxy. As printed: 6,010,712. View filing ↗
- Agios Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. View filing ↗
- Heron Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. View filing ↗
- Coherus BioSciences, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences's own proxy. As printed: 2,736,874. View filing ↗
- Karyopharm Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. View filing ↗
- Theravance Biopharma, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Theravance Biopharma's own proxy. As printed: 1,472,019. View filing ↗